Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

711883.pdf (418.77 KB)

Document type

Article

Version

Published version

Publication date

2021-04-23

Publication license

cc-by-nc (c) Darbà, Josep et al., 2021
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/185058

Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.2147/CEOR.S306389

Abstract

Objective: To determine the economic impact of the fraction of exhaled nitric oxide (FeNO) in asthma diagnosis and management in primary care in Sweden. Methods: An economic model has been developed to determine the economic impact of the fraction of exhaled nitric oxide (FeNO) in asthma diagnosis and management in primary care in Sweden. The model includes the use and cost of commonly used tests, the associated outcomes and diagnostic accuracy. We compared FeNO with spirometry and reversibility testing, methacholine challenge test, allergy testing, and blood eosinophil count. One-way sensitivity analyses were performed to confirm the robustness of results. Results: Adding FeNO measurement in asthma diagnosis resulted in cost savings of SEK 672 per patient by the fourth year. The use of FeNO testing in asthma management proved to be a dominant strategy when compared with each other test except methacholine challenge test. Sensitivity analyses confirmed the robustness of the results. Conclusion: Introducing FeNO testing in clinical practice for the diagnosis and management of asthma in primary care in Sweden is less costly than standard methods while providing similar health benefits.

Subject

Asma, Atenció primària, Gestió, Economia de la salut, Suècia

Subject (English)

Asthma, Primary care, Management, Medical economics, Sweden

Citation

Collections

Articles publicats en revistes (Economia)

Citation

DARBÀ, Josep, et al. Economic Evaluation of the Use of FeNO for the Diagnosis and Management of Asthma Patients in Primary Care in Sweden. Clinicoeconomics and Outcomes Research. 2021. Vol. 2021, num. 13, pags. 289-297. ISSN 1178-6981. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/185058

Export metadata

JSON - METS

Share record